A Novel Attenuated NADC30‐Like PRRSV Vaccine Candidate Provides Cross‐Protection Against Homologous and Heterologous Viral Challenge
Transboundary and Emerging Diseases · 2026-01 · 2026 (1)
DOI: 10.1155/tbed/5955745 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transboundary and Emerging Diseases, online erschienen am 05.07.2026. Verfasst von Heng Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: College of Veterinary Medicine, Northwest A&F University, Yangling, 712100, Shaanxi, China, nwsuaf.edu.cn. Hauptthemen laut MEDLINE: Porcine respiratory and reproductive syndrome virus, Porcine Reproductive and Respiratory Syndrome, Viral Vaccines, Cross Protection. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Key R&D Program of Shandong Province, China, Key International Cooperation Project of National Natural Science Foundation of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
Porcine reproductive and respiratory syndrome (PRRS) virus (PRRSV) is one of the major pathogens threatening the global swine industry and causes enormous economic losses annually. Vaccination remains one of the most important strategies for the prevention and control of PRRSV infection. In this study, a novel genotype 2 NADC30‐like PRRSV strain, designated AHFY, was isolated and characterized from eastern China. Phylogenetic analysis revealed that strain AHFY belonged to sublineage 1.8. An attenuated strain, AHFY‐F140, was obtained through 140 serial passages in MARC‐145 cells. Genomic sequence comparison between AHFY‐F140 and the parental strain AHFY‐F1 identified two discontinuous amino acid (aa) deletions in the nonstructural protein 2 (NSP2) gene, spanning residues 355–364 and 391–583, which were first detected at passage 90 and persisted through passage 140. The viral titer gradually increased with passaging, rising from 10 4.3 TCID 50 /mL for the parental strain AHFY‐F1 to 10 8.7 TCID 50 /mL for AHFY‐F140. A pathogenicity evaluation was conducted in 4‐week‐old PRRSV‐free New American Line piglets using AHFY‐F1 and AHFY‐F140. Piglets inoculated with AHFY‐F1 developed persistent fever and obvious respiratory clinical signs, accompanied by severe and typical histopathological lung lesions. In contrast, piglets inoculated with AHFY‐F140 showed no fever or other clinical signs. PRRSV‐specific antibodies became positive at 11 days postinoculation (dpi) in AHFY‐F140‐inoculated piglets, which was later than the 7 dpi observed in AHFY‐F1‐inoculated piglets. Furthermore, immunization with AHFY‐F140 provided robust protection against subsequent challenge with either the parental strain AHFY‐F1 or the highly pathogenic PRRSV (HP‐PRRSV) strain JXA1 (lineage 8). Collectively, these findings demonstrate that the attenuated strain AHFY‐F140 represents a promising vaccine candidate against both NADC30‐like and JXA1‐like PRRSV infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Veterinary Medicine, Northwest A&F University, Yangling, 712100, Shaanxi, China, nwsuaf.edu.cn.
- Swine Disease R&D Center, Shandong SINDER Technology Co.,Ltd., Qingdao, Shandong, 266104, China.
- Engineering Research Center of Efficient New Vaccines for Animals, Ministry of Education, Yangling, Shaanxi, 712100, China, moe.edu.cn.
- Key Laboratory of Ruminant Disease Prevention and Control (West), Ministry of Agriculture and Rural Affairs, Yangling, Shaanxi, 712100, China, agri.gov.cn.
ORCID-Profile: Heng Zhang, Jiakai Zhao, Chengxin Zhang, Ting Tang, Qianyi Zhu, Hui Zhou, Yingru Ma, Xiaohong Qi, Qin Zhao, Yani Sun
Förderung
- Key R&D Program of Shandong Province, China
- Key International Cooperation Project of National Natural Science Foundation of China
- National Natural Science Foundation of China
- Shaanxi Province Key Research and Development Program-Foreign Cooperation Field
Zitieren
APA
Zhang, H., Zhao, J., Zhang, C., Tang, T., Zhu, Q., Zhou, H., Ma, Y., Qi, X., Zhao, Q., & Sun, Y. (2026). A Novel Attenuated NADC30‐Like PRRSV Vaccine Candidate Provides Cross‐Protection Against Homologous and Heterologous Viral Challenge. Transboundary and Emerging Diseases, 2026(1). https://doi.org/10.1155/tbed/5955745
Vancouver
Zhang H, Zhao J, Zhang C, Tang T, Zhu Q, Zhou H, et al. A Novel Attenuated NADC30‐Like PRRSV Vaccine Candidate Provides Cross‐Protection Against Homologous and Heterologous Viral Challenge. Transboundary and Emerging Diseases. 2026;2026(1). doi:10.1155/tbed/5955745
BibTeX
@article{Zhang2026,
author = {Zhang, Heng and Zhao, Jiakai and Zhang, Chengxin and Tang, Ting and Zhu, Qianyi and Zhou, Hui and Ma, Yingru and Qi, Xiaohong and Zhao, Qin and Sun, Yani},
title = {A Novel Attenuated NADC30‐Like PRRSV Vaccine Candidate Provides Cross‐Protection Against Homologous and Heterologous Viral Challenge},
journal = {Transboundary and Emerging Diseases},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/tbed/5955745}
}
EUVIMED